Market capitalization | $877.92b |
Enterprise Value | $903.52b |
P/E (TTM) P/E ratio | 115.38 |
EV/FCF (TTM) EV/FCF | 3,504.73 |
EV/Sales (TTM) EV/Sales | 23.21 |
P/S ratio (TTM) P/S ratio | 22.56 |
P/B ratio (TTM) P/B ratio | 64.76 |
Dividend yield | 0.49% |
Last dividend (FY23) | $4.52 |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
32 Analysts have issued a Eli Lilly and Company forecast:
32 Analysts have issued a Eli Lilly and Company forecast:
Jun '24 |
+/-
%
|
||
Revenue | 11,303 11,303 |
36%
36%
|
|
Gross Profit | 9,133 9,133 |
40%
40%
|
|
EBITDA | 4,719 4,719 |
82%
82%
|
EBIT (Operating Income) EBIT | 4,304 4,304 |
94%
94%
|
Net Profit | 2,967 2,967 |
68%
68%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Head office | United States |
CEO | David Ricks |
Employees | 43,000 |
Founded | 1876 |
Website | www.lilly.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.